Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05432817
Other study ID # 2018-0630: WPP
Secondary ID A538900
Status Recruiting
Phase N/A
First received
Last updated
Start date January 4, 2024
Est. completion date January 2025

Study information

Verified date January 2024
Source University of Wisconsin, Madison
Contact Michael R Koenigs, PhD
Phone (608) 263-1679
Email mrkoenigs@wisc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study examining the psychological response to group Cognitive Processing Therapy (CPT) in incarcerated men and women with Post-traumatic stress disorder (PTSD). The study will be conducted in male and female incarcerated populations and will include 2 groups of 10 individuals for both CPT and Therapist-facilitated Support Group in both populations (i.e., 80 participants total; 40F/40M, four CPT groups of 10 (2 Female (F)/2 Male (M)); four Therapist-facilitated Support groups of 10 (2F/2M)). The study will run for up to 2 years. Participants can expect to be participating in study for up to 22 weeks.


Description:

Overall Study Objectives: The primary objectives of this project include: 1. Determine the effectiveness of CPT in reducing PTSD symptom severity; 2. Identify putative psychological mechanisms of response to CPT through pre-, mid-, and post-intervention measures of PTSD symptom severity as well as measures of hopelessness, self-blame, and negative self-related thoughts. Prior to beginning any study procedures, informed consent will be obtained orally and in writing. During the informed consent process, eligible participants will be provided with detailed information about the study, including their right to refuse or discontinue participation at any time and the fact that their decision to participate or decline will have no bearing on their standing within the criminal justice system. Potential participants will be contacted by calling them over the phone system within the prison. When they arrive to the private testing room, they are asked if they would like to learn about the study and potentially participate. If so, participants undergo consent. Eligible participants will first complete the Clinician-Administered PTSD Scale for DSM-5 (PCL-5) to ascertain current PTSD symptomology and diagnosis. This assessment will take approximately 90 minutes. Participants will then be assigned to the CPT or Therapist-facilitated Support groups. The CPT and Therapist-facilitated groups will engage in 12, 90-minute treatment sessions (18 hours total). CPT and Therapist-facilitated group-members are also asked to complete weekly homework (approximately 12 hours total). Approximately 10 participants will be included in each CPT or therapist-facilitated session. Participants with PTSD will be randomized to the CPT or therapist-facilitated groups. Participants will be notified via institutional mail when they are starting CPT or therapist-facilitated support. Participants in either group will be able to continue any ongoing treatment/interventions they are engaged in within the institution. All participants will be asked what treatment groups they are currently enrolled in during the initial screening to examine the possibility of attentional bias within the CPT group (i.e., more frequent interaction leading to treatment outcomes). In addition to the treatment groups, CPT and therapist-facilitated support group members will also complete a pre-treatment testing session two weeks prior to treatment week 1. During treatment week 3, CPT and therapist-facilitated support group members will complete mid-testing assessments. Participants will be called down individually to complete these assessments in a private room with a research assistant after completing the 5th therapy session, but before completing the 7th therapy session. CPT and therapist-facilitated group members will then complete post-testing within one week after completing week 6 of treatment. One and three months after the treatment is completed, CPT and therapist-facilitated group members will complete follow-up testing. Post- and one-month follow up- testing will follow the same procedure as pre- and mid-testing. CPT and therapist-facilitated group members will be asked to complete 17 sessions in total (pre-, mid-, post-, one-month follow up-testing, three-month follow-up testing, and 12 treatment groups).


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date January 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Participants will be enrolled from the Department of Corrections trauma treatment waitlist who have been screened for: - No active symptoms of psychosis that would interfere with the individual's ability to participate in the group - No active suicidal ideation with intent or plan - Able and willing to participate in group therapy Inclusion Criteria: - 18 years old or older - meet PCL-5 criteria for current PTSD diagnosis within 2 months of enrollment - no scheduled release date before the end of the treatment group - able to understand the consent form as measured by the consent quiz - no serious self-harm within past 6-months - no disciplinary segregation tim in past 6-months - have not participated in the previous CPT groups with UW project

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Processing Therapy
CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
Therapist-facilitated Support group
Therapist-facilitated Support: group therapy oriented toward providing general support networks and communities of individuals with similar experiences. Sessions will also focus on establishing trust, open communication, and developing therapeutic alliance with group members and the therapist facilitator. Occurs over 12 sessions.

Locations

Country Name City State
United States Psychiatric Institute and Clinic Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison Wisconsin Partnership Program

Country where clinical trial is conducted

United States, 

References & Publications (6)

Campbell CA, Albert I, Jarrett M, Byrne M, Roberts A, Phillip P, Huddy V, Valmaggia L. Treating Multiple Incident Post-Traumatic Stress Disorder (PTSD) in an Inner City London Prison: The Need for an Evidence Base. Behav Cogn Psychother. 2016 Jan;44(1):112-7. doi: 10.1017/S135246581500003X. Epub 2015 Feb 20. — View Citation

Egeressy A, Butler T, Hunter M. 'Traumatisers or traumatised': Trauma experiences and personality characteristics of Australian prisoners. Int J Prison Health. 2009;5(4):212-22. doi: 10.1080/17449200903343209. — View Citation

James, D.J. and L.E. Glaze, Mental health problems of prison and jail inmates, U.S.D.o. Justice, Editor. 2006: Bureau of Justice Statistics Special Report.

Morgan RD, Winterowd CL. Interpersonal process-oriented group psychotherapy with offender populations. Int J Offender Ther Comp Criminol. 2002 Aug;46(4):466-82. doi: 10.1177/0306624X02464008. — View Citation

Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002 Aug;70(4):867-79. doi: 10.1037//0022-006x.70.4.867. — View Citation

Resick, P.A., C.M. Monson, and K.M. Chard, Cognitive Processing Therapy for PTSD: A Comprehensive Manual. 2016: Guilford Press.

Outcome

Type Measure Description Time frame Safety issue
Primary Change in PTSD Checklist for DSM-5 (PCL-5) severity score PTSD symptom severity is measured by PCL-5 questionnaire (scores from 0, no symptoms, to 80, high severity); primary measure of intervention efficacy baseline (two weeks prior to intervention), up to 3 weeks (mid-intervention), up to 8 weeks (one week post-intervention), up to 12 weeks (one month post-treatment), and up to 20 weeks (three months post-treatment)
Secondary Change in score on the Beck Depression Inventory 2 (BDI-II) Depression level measured by score on BDI-II (between 0 and 63; over 40 = extreme depression); secondary measure of intervention efficacy baseline (two weeks prior to intervention), up to 3 weeks (mid-intervention), up to 8 weeks (one week post-intervention), and up to 12 weeks (one month post-treatment)
Secondary Change in score on the Beck Anxiety Inventory (BAI) Anxiety level measured by score on BAI (between 0 and 63; over 30 = severe anxiety); secondary measure of intervention efficacy baseline (two weeks prior to intervention), up to 3 weeks (mid-intervention), up to 8 weeks (one week post-intervention), up to 12 weeks (one month post-treatment), and up to 20 weeks (three months post-treatment)
Secondary Percentage of participants endorsing 2 or higher on Q9 of BDI-II Question 9 on the BDI-II assesses for suicidal ideation. A score of 2 (I would like to kill myself) or 3 (I would kill myself if I had the chance; the highest score) indicate heightened levels of suicidal ideation. Participants who endorse current suicidal ideation will be referred to mental health services within the institution. baseline (two weeks prior to intervention), up to 3 weeks (mid-intervention), up to 8 weeks (one week post-intervention), up to 12 weeks (one month post-treatment), and up to 20 weeks (three months post-treatment)
Secondary Ratings from 0-5 by clinical supervisors on therapist adherence to five session elements Higher ratings indicate better adherence to session elements. Assesses for therapist adherence to CPT guidelines as secondary measure of intervention efficacy. For each 12-session intervention, 2 sessions will be audiotaped and rated. Up to 7 weeks (by the end of the 12th session)
Secondary Ratings 1-7 by clinical supervisors on quality of session elements delivered by therapist Higher ratings indicate higher-quality session element (scores 1-7;1="not satisfactory", 4="satisfactory", 7="excellent") by the clinical supervisors. Competence ratings will be collected for two audiotaped group sessions out of each 12-session intervention. Assesses for therapist compliance as secondary measure of intervention efficacy. Up to 7 weeks (by the end of the 12th session)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03962504 - Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT06278922 - Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma N/A
Completed NCT04597450 - Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD) Phase 1
Completed NCT03593772 - Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD N/A
Completed NCT03429166 - Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas N/A
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT03504722 - Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD N/A
Completed NCT04305353 - Intensive Care Unit (ICU) Diary Project N/A
Completed NCT03113890 - McLean and Genomind Prospective Study N/A
Withdrawn NCT05173831 - Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans Phase 2
Not yet recruiting NCT05921929 - First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Phase 1
Withdrawn NCT03924297 - Chilipad for Sleep and Symptoms of PTSD N/A
Not yet recruiting NCT04056767 - Changes in Digital Phenotype During PE Therapy
Completed NCT03343028 - Biomarker Establishment for Superior Treatment of PTSD
Withdrawn NCT03216356 - Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD Phase 2/Phase 3
Completed NCT03158558 - Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD N/A
Completed NCT02370173 - A Non-Pharmacological Method for Enhancing Sleep in PTSD N/A
Completed NCT01955538 - The Effect of BAT Versus Mixed Physical Activity as add-on Treatment for Traumatised Refugees. Phase 3